Novo reports early bone-protection signals from amylin and calcitonin receptor agonists

Key highlights
  • After eight weeks in ovariectomized rats, femoral trabecular bone volume was 43% higher with cagrilintide and 40% higher with CagriSema than in weight-matched controls; both differences were significant.
  • Small studies in healthy volunteers linked cagrilintide and zenagamtide, but not selective amylin receptor agonist NN1213, to lower levels of the bone-resorption marker CTX-I.
  • In a 252-participant REDEFINE 1 DXA substudy, bone mineral density declined with CagriSema but remained within the normal range for age and sex at week 68.
  • REDEFINE 1 was not designed to assess fracture risk, and the exploratory findings require further study.

Preclinical findings

In an eight-week model of postmenopausal bone loss, cagrilintide and CagriSema attenuated trabecular bone loss and deterioration of bone microarchitecture. Femoral trabecular bone volume was 43% higher with cagrilintide and 40% higher with CagriSema than in weight-matched controls, with both differences statistically significant. Increases with zenagamtide and semaglutide were not significant.

Human biomarker and trial analyses

Small studies in healthy volunteers found that cagrilintide and zenagamtide suppressed CTX-I, a marker of bone resorption; selective amylin receptor agonist NN1213 did not show the same effect. The comparison suggests calcitonin receptor activation may contribute to the observed effect.

In post hoc analyses of phase 3 REDEFINE 1, bone mineral density decreased among CagriSema-treated participants in a 252-person DXA substudy but remained within the normal range for age and sex at week 68. CTX-I increased similarly to placebo with cagrilintide and modestly more with CagriSema than with semaglutide, despite greater weight loss. The bone-formation marker P1NP rose above baseline by week 68, while proteins associated with bone formation and mineralization increased with cagrilintide and CagriSema.

Limitations

The analyses are exploratory, and REDEFINE 1 was not designed to assess fracture risk. Longer follow-up and further research are needed to establish whether the findings translate into long-term bone health outcomes. The medicines are investigational.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

7 June 2026
Novo Nordisk CagriSema Phase 3 trials show large HbA1c and weight reductions

Once‑weekly cagrilintide+semaglutide reduced HbA1c by up to 2.33 percentage points and bodyweight by up to 14.2% across REIMAGINE 1–3 versus comparators.

16 September 2025
Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results

Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

5 June 2026
Novo Nordisk zenagamtide (amycretin) delivers large HbA1c and weight reductions in phase 2 T2D trial

Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.

15 November 2026
Novo reports 25.4% mean weight loss among early CagriSema responders

A post hoc analysis of REDEFINE 1 found 67.8% reached at least 5% weight loss by week 8; separate analyses reported improved physical and psychosocial function.